Pharmos Corporation (Pharmos) is a biopharmaceutical company that discovers and develops therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. Pharmos owns the rights to both R and S Tofisopam. These are the two enantiomers of racemic tofisopam that has been used outside the United States. The Companyâ€™s primary focus is on the development and partnering of Levotofisopam and Dextofisopam. The Company's product Dextofisopam is used for the treatment of irritable bowel syndrome (IBS). Dextofisopam is the R enantiomer of racemic tofisopam. Levotofisopam is the S-enantiomer of the racemic mixture RS-tofisopam.